Julien Fourcade

3.5k citations

22 papers · 2.8k indexed · 2 hit papers · h-index 12

Impact in

Immunology top 1%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Galectins and Cancer Biology
- Immune cells in cancer
Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis

Papers in

Immunology 19
- Immunotherapy and Immune Responses 13
- Immune Cell Function and Interaction 8
- T-cell and B-cell Immunology 5
- Galectins and Cancer Biology 2
- Toxin Mechanisms and Immunotoxins 2
Oncology 14
- CAR-T cell therapy research 11
- Cancer Immunotherapy and Biomarkers 10

Co-authors: Hassane M. Zarour John M. Kirkwood Cindy Sander Zhaojun Sun Immanuel F. Luescher Philippe Guillaume Vijay K. Kuchroo Ornella Pagliano
Journals: The Journal of Immunology (6 papers)Cancer Research (4 papers)Journal of Clinical Oncology (3 papers)Drug Metabolism and Disposition (1 paper)The Journal of Experimental Medicine (1 paper)
Partner nations: United States Switzerland France

In The Last Decade

Julien Fourcade

21 papers receiving 2.7k citations

Hit Papers

align trajectories log scale

TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients 2015 · 608 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 Journal of Clinical Investigation
2010 The Journal of Experimental Medicine

Peers

Countries citing papers authored by Julien Fourcade

Since Specialization

Citations

This map shows the geographic impact of Julien Fourcade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julien Fourcade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julien Fourcade more than expected).

Fields of papers citing papers by Julien Fourcade

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julien Fourcade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julien Fourcade. The network helps show where Julien Fourcade may publish in the future.

Co-authors

The 25 scholars most cited alongside Julien Fourcade, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Julien Fourcade Line = papers co-authored together Julien Fourcade links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Such a long wait: Three-dimensional paediatric transoesophageal echocardiography finally arises Archives of cardiovascular diseases ·Philippe Acar, Khaled Hadeed, Carson C Roan, ZhengXin Zhang, Kyo A, Yves Dulac, 稲葉麻美, Julien Fourcade, Yoan Lavie‐Badie, Nicolas Combes, Milou Luijks, Davide Calvaruso, Clément Karsenty	2022	3
2	CD226 opposes TIGIT to disrupt Tregs in melanoma JCI Insight ·Julien Fourcade, Zhaojun Sun, Joë-Marc Chauvin, Mignane Ka, Diwakar Davar, Ornella Pagliano, Hong Wang, Sofiane Saada, Carmine Menna, Rada Amin, Cindy Sander, John M. Kirkwood, Alan J. Korman, Hassane M. Zarour	2018	149
3	Tolerance analysis using a Computer Aided Tolerancing Software: ANATOLE 3D Procedia CIRP ·Y.W. Choi, Cominf, Julien Fourcade	2018	4
4	Phase IB study of pembrolizumab (Pembro) and pegylated-interferon alfa-2b (Peg-IFN) in advanced melanoma (MEL). Journal of Clinical Oncology ·Diwakar Davar, Hong Wang, Joë-Marc Chauvin, Zhaojun Sun, Ornella Pagliano, Amy Rose, Liban Muhudin Alim, Cindy Sander, Julien Fourcade, Uma N. M. Rao, Nageatte Ibrahim, Scot Ebbinghaus, Hussein Tawbi, Ahmad A. Tarhini, John M. Kirkwood, Hassane M. Zarour, Giuseppe Lo Russo	2016	2
5	IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells Cancer Research ·Zhaojun Sun, Julien Fourcade, Ornella Pagliano, Joë-Marc Chauvin, Cindy Sander, John M. Kirkwood, Hassane M. Zarour	2015	141
6	Study of anti-PD-1 antibody pembrolizumab and pegylated-interferon alfa-2b (Peg-IFN) for advanced melanoma. Journal of Clinical Oncology ·Hassane M. Zarour, Hussein Tawbi, Ahmad A. Tarhini, Hong Wang, Cindy Sander, Amy Rose, Julien Fourcade, Joë-Marc Chauvin, Zhaojun Sun, Ornella Pagliano, John M. Kirkwood	2015	7
7	Abstract 4046: Interleukin-10 and programmed death-1 cooperate to regulate tumor antigen-specific CD8+ T cells in melanoma patients Cancer Research ·Zhaojun Sun, Julien Fourcade, Ornella Pagliano, Joë-Marc Chauvin, Cindy Sander, John M. Kirkwood, Hassane M. Zarour	2015	1
8	TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients Journal of Clinical Investigation ·Joë-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sander, John M. Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J. Korman, Hassane M. Zarour Hit paper breakdown →	2015	608
9	Tim-3 is expressed by a majority of NK cells at periphery but not at tumor site in patients with advanced melanoma (TUM2P.919) The Journal of Immunology ·Zhaojun Sun, Julien Fourcade, Ornella Pagliano, Joë-Marc Chauvin, Cindy Sander, John M. Kirkwood, Vijay K. Kuchroo, Hassane M. Zarour	2014	1
10	PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen–Specific CD8+ T Cells Induced by Melanoma Vaccines Cancer Research ·Julien Fourcade, Zhaojun Sun, Ornella Pagliano, 昭一小沢, Cindy Sander, Bratislav Janjic, Ahmad A. Tarhini, Hussein A. Tawbi, John M. Kirkwood, Stergios J. Moschos, Hong Wang, Philippe Guillaume, Immanuel F. Luescher, Arthur Μ. Krieg, Ana C. Anderson, Vijay K. Kuchroo, Hassane M. Zarour	2013	175
11	Strategies to reverse melanoma-induced T-cell dysfunction Clinics in Dermatology ·Julien Fourcade, Hassane M. Zarour	2013	7
12	CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1 Cancer Research ·Julien Fourcade, Zhaojun Sun, Ornella Pagliano, Philippe Guillaume, Immanuel F. Luescher, Cindy Sander, John M. Kirkwood, Daniel Olive, Vijay K. Kuchroo, Hassane M. Zarour	2011	291
13	Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients The Journal of Experimental Medicine ·Julien Fourcade, Zhaojun Sun, Mourad Benallaoua, Philippe Guillaume, Immanuel F. Luescher, Cindy Sander, John M. Kirkwood, Vijay K. Kuchroo, Hassane M. Zarour Hit paper breakdown →	2010	1032
14	Human Tumor Antigen-Specific Helper and Regulatory T Cells Share Common Epitope Specificity but Exhibit Distinct T Cell Repertoire The Journal of Immunology ·Julien Fourcade, Zhaojun Sun, Pavol Kudela, Bratislav Janjic, John M. Kirkwood, HIETALA RAMI, Hassane M. Zarour	2010	36
15	Epitope Hierarchy of Spontaneous CD4+ T Cell Responses to LAGE-1 The Journal of Immunology ·Pavol Kudela, Zhaojun Sun, Julien Fourcade, Bratislav Janjic, John M. Kirkwood, Bernard Maillère, Hassane M. Zarour	2010	6
16	PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients The Journal of Immunology ·Julien Fourcade, Pavol Kudela, Zhaojun Sun, Hongmei Shen, Stephanie R. Land, Diana Lenzner, Philippe Guillaume, Immanuel F. Luescher, Cindy Sander, Soldano Ferrone, John M. Kirkwood, Hassane M. Zarour	2009	131
17	Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients Journal of Immunotherapy ·Julien Fourcade, Pavol Kudela, Pedro A. Andrade Filho, Bratislav Janjic, Stephanie R. Land, Cindy Sander, Arthur Μ. Krieg, Albert D. Donnenberg, Hongmei Shen, John M. Kirkwood, Hassane M. Zarour	2008	90
18	Cross-Reactive CD4+ T Cells against One Immunodominant Tumor-Derived Epitope in Melanoma Patients The Journal of Immunology ·Pavol Kudela, Bratislav Janjic, Julien Fourcade, Florence Castelli, J. Linek, John M. Kirkwood, Talal El‐Hefnawy, Massimo Amicosante, Bernard Maillère, Hassane M. Zarour	2007	6
19	Spontaneous CD4+ T Cell Responses against TRAG-3 in Patients with Melanoma and Breast Cancers The Journal of Immunology ·Bratislav Janjic, J. Linek, Xiaofei Wang, Julien Fourcade, Christine Almunia, Pavol Kudela, Adam Brufsky, Samuel A. Jacobs, David Friedland, Ronald G. Stoller, Daniel Gillet, Ronald B. Herberman, John M. Kirkwood, Bernard Maillère, Hassane M. Zarour	2006	15
20	IN VITRO METABOLISM OF THE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR, WORTMANNIN, BY CARBONYL REDUCTASE Drug Metabolism and Disposition ·Julianne L. Holleran, Julien Fourcade, Merrill J. Egorin, Julie L. Eiseman, Robert A. Parise, Steven M. Musser, Kevin D. White, Joseph M. Covey, Gerald L. Forrest, Su‐Shu Pan	2004	15

About Julien Fourcade

Julien Fourcade is a scholar working on Immunology, Oncology, Biochemistry, Industrial and Manufacturing Engineering and Cell Biology, having authored 22 papers that have together received 2.8k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (13 papers), CAR-T cell therapy research (11 papers), Cancer Immunotherapy and Biomarkers (10 papers), Immune Cell Function and Interaction (8 papers), T-cell and B-cell Immunology (5 papers), vaccines and immunoinformatics approaches (3 papers), Galectins and Cancer Biology (2 papers) and Toxin Mechanisms and Immunotoxins (2 papers). The work is most often cited by research in Immunology (2.2k citations), Oncology (2.1k citations), Pathology and Forensic Medicine (126 citations), Genetics (74 citations) and Molecular Biology (378 citations). Julien Fourcade has collaborated with scholars based in United States, Switzerland and France. Frequent co-authors include Hassane M. Zarour, John M. Kirkwood, Cindy Sander, Zhaojun Sun, Immanuel F. Luescher, Philippe Guillaume, Vijay K. Kuchroo, Ornella Pagliano, Mourad Benallaoua and Joë-Marc Chauvin. Their work appears in journals such as The Journal of Immunology, Cancer Research, Journal of Clinical Oncology, Drug Metabolism and Disposition and The Journal of Experimental Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact